Immune checkpoint inhibitors: friend or foe for osteoporosis.
作者信息
Tang Jun
机构信息
Department of Endocrinology, Zhongnan Hospital of Wuhan University, 169 East Lake Rd., Wuhan 430071, China.
出版信息
Ther Adv Endocrinol Metab. 2023 Mar 1;14:20420188231157194. doi: 10.1177/20420188231157194. eCollection 2023.
Abstract
摘要
相似文献
1
Immune checkpoint inhibitors: friend or foe for osteoporosis.免疫检查点抑制剂：骨质疏松症的朋友还是敌人？
Ther Adv Endocrinol Metab. 2023 Mar 1;14:20420188231157194. doi: 10.1177/20420188231157194. eCollection 2023.
2
Editorial: Glucocorticoid and bone: Friend or foe.社论：糖皮质激素与骨骼：是友还是敌。
Front Endocrinol (Lausanne). 2022 Aug 11;13:995124. doi: 10.3389/fendo.2022.995124. eCollection 2022.
3
TNF in the era of immune checkpoint inhibitors: friend or foe?免疫检查点抑制剂时代的肿瘤坏死因子：是友还是敌？
Nat Rev Rheumatol. 2021 Apr;17(4):213-223. doi: 10.1038/s41584-021-00584-4. Epub 2021 Mar 8.
4
A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?复发或难治性非霍奇金淋巴瘤免疫检查点疗法的系统评价和荟萃分析：是友还是敌？
Transl Oncol. 2023 Apr;30:101636. doi: 10.1016/j.tranon.2023.101636. Epub 2023 Feb 9.
5
Obesity: Friend or foe for osteoporosis.肥胖：骨质疏松症的朋友还是敌人？
J Midlife Health. 2014 Jan;5(1):6-9. doi: 10.4103/0976-7800.127782.
6
Poster 101 Osteoporosis and Bisphosphonate Therapy: Friend or Foe? A Case Report.海报101：骨质疏松症与双膦酸盐治疗：是福是祸？病例报告。
PM R. 2016 Sep;8(9S):S194-S195. doi: 10.1016/j.pmrj.2016.07.144. Epub 2016 Sep 24.
7
[Microbial "friend-foe" identification in human intestine microsymbiocenosis].[人体肠道微共生群落中微生物“敌友”识别]
Zh Mikrobiol Epidemiol Immunobiol. 2011 Nov-Dec(6):46-51.
8
Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?胃肠道肿瘤中的抗生素与免疫疗法：是友还是敌？
World J Clin Cases. 2019 Jun 6;7(11):1253-1261. doi: 10.12998/wjcc.v7.i11.1253.
9
TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer?TNFα 与免疫检查点抑制：肺癌的友军还是敌军？
Int J Mol Sci. 2021 Aug 13;22(16):8691. doi: 10.3390/ijms22168691.
10
Dinucleoside polyphosphates-friend or foe?二核苷多磷酸——是友还是敌？
Pharmacol Ther. 2000 Aug-Sep;87(2-3):73-89. doi: 10.1016/s0163-7258(00)00041-3.
引用本文的文献
1
The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management.PD-1/PD-L1抑制剂对骨代谢的调节作用：骨质疏松症管理中的机遇与挑战
Front Immunol. 2025 Jul 25;16:1630751. doi: 10.3389/fimmu.2025.1630751. eCollection 2025.
2
Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study.免疫检查点抑制剂所致肌肉骨骼不良事件：一项大规模药物警戒研究
Front Pharmacol. 2023 Oct 10;14:1199031. doi: 10.3389/fphar.2023.1199031. eCollection 2023.
本文引用的文献
1
Immune-checkpoint inhibitors: long-term implications of toxicity.免疫检查点抑制剂：毒性的长期影响。
Nat Rev Clin Oncol. 2022 Apr;19(4):254-267. doi: 10.1038/s41571-022-00600-w. Epub 2022 Jan 26.
2
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.骨骨折作为一种新型免疫相关不良事件与免疫检查点抑制剂：病例系列和大规模药物警戒分析。
Int J Cancer. 2021 Aug 1;149(3):675-683. doi: 10.1002/ijc.33592. Epub 2021 May 4.
3
PD-1 blockade inhibits osteoclast formation and murine bone cancer pain.PD-1 阻断抑制破骨细胞形成和小鼠骨癌痛。
J Clin Invest. 2020 Jul 1;130(7):3603-3620. doi: 10.1172/JCI133334.
4
Potential diagnostic value of PD-1 in peripheral blood mononuclear cells of postmenopausal osteoporosis patients.绝经后骨质疏松症患者外周血单个核细胞中 PD-1 的潜在诊断价值。
J Clin Lab Anal. 2020 Jun;34(6):e23223. doi: 10.1002/jcla.23223. Epub 2020 Feb 17.
5
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.免疫检查点抑制剂相关骨骼免疫不良反应：一项重要的病例系列研究。
J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.
6
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.破骨细胞在多发性骨髓瘤中的免疫抑制作用：程序性细胞死亡配体 1 的作用。
Front Immunol. 2018 Aug 10;9:1822. doi: 10.3389/fimmu.2018.01822. eCollection 2018.
7
Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity.更新骨免疫学：固有免疫和适应性免疫对骨细胞的调节。
Nat Rev Rheumatol. 2018 Mar;14(3):146-156. doi: 10.1038/nrrheum.2017.213. Epub 2018 Jan 11.
8
Cytokines in immunogenic cell death: Applications for cancer immunotherapy.细胞因子在免疫原性细胞死亡中的作用：在癌症免疫治疗中的应用。
Cytokine. 2017 Sep;97:123-132. doi: 10.1016/j.cyto.2017.05.024. Epub 2017 Jun 22.
9
The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis.免疫调节受体PD-1的缺陷会导致轻度骨质石化。
Bone. 2004 Nov;35(5):1059-68. doi: 10.1016/j.bone.2004.06.018.
Zotero 插件